• Home
  • Internation Expansion
  • Expanded Elkton, Virginia manufacturing facility to further increase MSD’s HPV vaccine supply and support broader and equitable access

Expanded Elkton, Virginia manufacturing facility to further increase MSD’s HPV vaccine supply and support broader and equitable access

By on April 6, 2022 0
Download logo

MSD (NYSE: MRK) (www.MSD.com), a trade name of Merck & Co., Inc, Kenilworth, NJ, USA, has reaffirmed its commitment to enabling broad and equitable access to HPV vaccines from society. To support this, the company has invested significantly in manufacturing and recently expanded its vaccine manufacturing facility located in Elkton, Va., completing the construction of 120,000 square feet on site to further increase capacity and capacity. supply of the company’s human papillomavirus (HPV) vaccines. , following regulatory reviews and approvals.

“As we continue to scale up production of our HPV vaccines, we are prioritizing access in high-burden countries, including countries eligible for Gavi and UNICEF support,” said said Dr. Priya Agrawal, global head of HPV vaccines at MSD. “As part of our long-term agreement with UNICEF, we plan to supply 91.5 million doses of our HPV vaccines for use in Gavi-supported countries from 2021 to 2025, and we have donated doses additional beyond this agreement as needed to meet growing demand. ”

“Increasing the supply of our HPV vaccines is a top priority, and over the past few years we have steadily increased our manufacturing capacity in response to growing global demand,” said Jacks Lee, vice-president senior president, MSD Manufacturing. “Despite the pandemic, our teams completed the building infrastructure expansion at our Elkton site ahead of schedule and we are delighted to reach this important milestone.”

In 2019, MSD committed more than $1 billion to expand production capacity at existing manufacturing facilities and build new facilities to meet unprecedented global demand for our HPV vaccines. MSD has expanded and optimized its existing facilities, nearly doubling the supply of our HPV vaccines from 2017 to 2020, and has continued to increase supply in recent years.

MSD expects the supply of its HPV vaccines to double again between 2020 and 2023 as the company continues to expand capacity at existing facilities and as new facilities come online.

Distributed by APO Group on behalf of MSD.

Media contacts:
Julie Cunningham
(617) 519-6264

Steve Wanczyk
(267) 481-0074

Investor contacts:
Pierre Dannenbaum
(908) 740-1037

About MSD:
For more than 130 years, MSD has been inventing for life, providing medicines and vaccines for many of the world’s toughest diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patient and population health by improving access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten humans and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company. in the world. For more information, visit www.MSD.com and connect with us on Twitter (https://bit.ly/3jdgBzv), LinkedIn (https://bit.ly/3DHQfiw) and YouTube (https:/ /bit.ly/36R4buJ).

Merck & Co., Inc., Kenilworth, NJ, USA Forward-Looking Statement:
This press release from Merck & Co., Inc., Kenilworth, NJ, USA (the “Company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995 These statements are based on the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and around the world; global trends toward health care cost containment; technological advances, new products and patents obtained by competitors; challenges inherent in developing new products, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and exposure to litigation, including patent litigation, and/or regulatory actions.

The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Other factors that could cause results to differ materially from those described in the forward-looking statements can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 and other company filings. with the Securities and Exchange Commission. (SEC) available on the SEC’s website (www.Sec.gov).

This press release was issued by APO. Content is not vetted by the African Business editorial team and none of the content has been verified or validated by our editorial teams, proofreaders or fact checkers. The issuer is solely responsible for the content of this announcement.